Skip to main content
BALCHEM CORP logo

BALCHEM CORP — Investor Relations & Filings

Ticker · BCPC ISIN · US0576652004 LEI · 549300VR70OPMHUI3557 US Manufacturing
Open in API
Filings indexed 1,262 across all filing types
Latest filing 2010-01-29 Director's Dealing
Country US United States of America
Listing US BCPC

About BALCHEM CORP

https://balchem.com/

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products. The company operates through three primary segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products. The Human Nutrition & Health division is a leader in essential nutrients like choline, chelated minerals, and vitamin K2, utilizing advanced microencapsulation technologies for the food and nutritional supplement markets. The Animal Nutrition & Health segment provides a portfolio of products to meet the nutritional needs of animals, with a key position in choline chloride. The Specialty Products segment includes Performance Gases for various industrial applications and Plant Nutrition solutions. Balchem is focused on delivering innovative, science-based solutions to improve health and nutrition.

Recent filings

Filing Released Lang Actions
4
Director's Dealing
2010-01-29 English
Regulatory Filings 2010
Regulatory Filings Classification · 95% confidence The document is a detailed letter response from Balchem Corporation to the SEC regarding comments on their Form 10-K for the fiscal year ended December 31, 2008, and their Definitive Proxy Statement on Schedule 14A filed April 28, 2009. The letter addresses specific SEC comments on disclosures related to business risks, MD&A, contractual obligations, financing activities, comprehensive income, and executive compensation disclosures. The presence of detailed responses to SEC comments on the 10-K and proxy statement, including references to Regulation S-K items and executive compensation disclosures, indicates this is a comment letter and response rather than the actual 10-K or proxy statement filings themselves. The document is not a full annual report or proxy statement but a regulatory filing responding to SEC review comments. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such correspondence and compliance documents that do not constitute the actual report or statement filings.
2010-01-29 English
Major Shareholding Notification 2010
Major Shareholding Notification
2010-01-29 English
Major Shareholding Notification 2010
Major Shareholding Notification
2010-01-27 English
Regulatory Filings 2009
Regulatory Filings Classification · 80% confidence The document text appears to be an encoded or binary attachment (e.g., a uuencoded PDF file) rather than readable text. There are no discernible keywords, regulatory references, form names, fiscal period dates, or document titles that indicate the nature of the filing. The length is about 15,000 characters, which is substantial, but without readable content or metadata indicating the filing type, it is impossible to classify it as a specific report or announcement. Given the lack of identifiable information and the fallback rule, the document should be classified as a Regulatory Filing (RNS).
2009-12-30 English
Director's Dealing 2009
Director's Dealing
2009-12-11 English

Browse filings by year

32 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.